Capturing the Value of R&D
Executive Summary
Worried about a likely gap in earnings, many drug companies want to increase the number of products in their pipelines. But such productivity driven strategies hav estrained development and commercialization resources while advancing mediocre compounds, compromising marketplace results. Yield-led companies have done far better, focusing on fewer, better products and devoting adequate resources to their development and launch.